{"nctId":"NCT05501860","briefTitle":"A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution","startDateStruct":{"date":"2022-07-30","type":"ACTUAL"},"conditions":["Anesthesia, Local"],"count":249,"armGroups":[{"label":"AG-920","type":"EXPERIMENTAL","interventionNames":["Drug: AG-920"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"AG-920","otherNames":["articaine"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Provide written informed consent prior to any study-related procedures being performed.\n2. Male or a non-pregnant, non-lactating female.\n3. Healthy by clinical assessment, including ocular examination.\n4. Have an Early Treatment of Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA) of 20/200 or better in both eyes.\n5. Have an Intraocular Pressure (IOP) between 7 and 30 mmHg.\n\n   Specular microscopy subset subjects only:\n6. Have a central corneal endothelial cell density of ≥1500 cells/mm2 at baseline\n\nExclusion Criteria:\n\n1. . Have participated in an investigational study within the past 30 days.\n2. Have a contraindication to local anesthetics, Septocaine®, or any component of the IMP.\n3. Have had ocular surgery or general surgery in either eye within the past 90 days.\n4. Have had an intravitreal injection in either eye within 14 days of randomization.\n5. Have ocular surface disease requiring punctal plugs.\n6. Have evidence of any current ocular inflammation.\n7. Current ocular allergy symptoms.\n8. Have used topical, ocular medications in the 24 hours preceding dosing.\n9. Systemic opioid, opiate analgesic or topical Non-steroidal Anti-Inflammatory Drug (NSAID) use within the past 30 days.\n10. Previous participation in a clinical study of AG-920.\n11. A current condition which could cause vision problems such as Pseudotumor Cerebri.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","description":"TEAEs will be summarized by treatment group using frequency and percent for each system, organ, class (SOC) and preferred term within each SOC.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Corneal Endothelial Cell Density After Treatment With AG-920","description":"Endothelial cell count (and corneal morphology) will be summarized by continuous summaries","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.83","spread":"92.18"},{"groupId":"OG001","value":"-44.33","spread":"85.19"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":166},"commonTop":["Instillation site pain"]}}}